



Blood glucose levels and COVID-19. Reply to Sardu C, D'Onofrio N, Balestrieri ML et al [letter] and Lepper PM, Bals R, Jüni P et al [letter]

Bertrand Cariou, Samy Hadjadj, Matthieu Wargny, Matthieu Pichelin, Abdallah Al-Salameh, Ingrid Allix, Coralie Amadou, Gwénaëlle Arnault, Florence Baudoux, Bernard Bauduceau, et al.

► To cite this version:

Bertrand Cariou, Samy Hadjadj, Matthieu Wargny, Matthieu Pichelin, Abdallah Al-Salameh, et al.. Blood glucose levels and COVID-19. Reply to Sardu C, D'Onofrio N, Balestrieri ML et al [letter] and Lepper PM, Bals R, Jüni P et al [letter]. *Diabetologia*, 2020, 63 (11), pp.2491-2494. 10.1007/s00125-020-05255-9 . hal-02935425

HAL Id: hal-02935425

<https://hal.sorbonne-universite.fr/hal-02935425>

Submitted on 12 Nov 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Blood glucose levels and COVID-19. Reply to Sardu C, D'Onofrio N, Balestrieri ML et al [letter] and Lepper PM, Bals R, Jüni P et al [letter]

Bertrand Cariou¹ · Samy Hadjadj¹ · Matthieu Wargny^{1,2} · Matthieu Pichelin¹ · Abdallah Al-Salameh³ · Ingrid Allix⁴ · Coralie Amadou⁵ · Gwénaëlle Arnault⁶ · Florence Baudoux⁷ · Bernard Bauduceau^{8,9} · Sophie Borot¹⁰ · Muriel Bourgeon-Ghittori¹¹ · Olivier Bourron¹² · David Boutoille¹³ · France Cazenave-Roblot^{14,15} · Claude Chaumeil¹⁶ · Emmanuel Cosson^{17,18} · Sandrine Coudol² · Patrice Darmon¹⁹ · Emmanuel Disse²⁰ · Amélie Ducet-Boiffard²¹ · Bénédicte Gaborit²² · Michael Joubert²³ · Véronique Kerlan²⁴ · Bruno Laviolle²⁵ · Lucien Marchand²⁶ · Laurent Meyer²⁷ · Louis Potier²⁸ · Gaëtan Prevost²⁹ · Jean-Pierre Riveline^{30,31,32} · René Robert³³ · Pierre-Jean Saulnier³⁴ · Ariane Sultan³⁵ · Jean-François Thébaut¹⁶ · Charles Thivolet^{36,37} · Blandine Tramunt³⁸ · Camille Vatie^{39,40} · Ronan Roussel²⁸ · Jean-François Gautier^{30,32} · Pierre Gourdy³⁸ · for the CORONADO investigators

Keywords Blood glucose · COVID-19 · Diabetes · Mortality · Prognosis

Abbreviations

CAP Community-acquired pneumonia
COVID-19 Coronavirus disease-2019

To the Editor: We welcome the letters by Sardu et al [1] and Lepper et al [2] on our paper entitled ‘Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study’ [3]. Sardu et al found that the change in blood glucose concentration between admission and 24 h was associated with coronavirus disease-2019 (COVID-19) outcome in 132 Italian hyperglycaemic (i.e. blood glucose >7.7 mmol/l on admission) patients hospitalised for both severe and non-severe disease [1]. In addition, Lepper et al reported data on an impressive cohort of nearly 7000 patients with community-acquired pneumonia (CAP) and

demonstrated that elevated blood glucose on admission was associated with an increased risk of death in individuals with or without pre-existing diabetes [2, 4]. Both studies emphasised the value of admission blood glucose on prognosis of COVID-19 and of CAP [2].

Sardu et al considered that we misinterpreted our data on admission blood glucose, since we claimed that we considered it to be a consequence of, rather than a contributor to COVID-19 severity. This point is of scientific and medical interest. They acknowledged a prognostic role for admission blood glucose, which is in line with our findings, and, furthermore, suggested that hyperglycaemia is more than a simple marker of the severity of the infection. We believe that their interesting results should not lead to any alteration of our conclusion on the value of admission blood glucose for several reasons. First, the study by Sardu et al was purely observational and so causation cannot be established: the greater decrease in blood glucose between those with a better outcome compared with the others does not imply that this improvement is causal. Second, Van den Berghe et al could not find evidence of a benefit on all-cause death of strict blood glucose control with insulin compared with conventional therapy in a study of 1200 patients admitted to the medical ICU, with half of the participants having respiratory conditions [5].

We fully agree with Lepper et al that admission blood glucose can be used as a stratification factor to identify patients at high risk of severe pneumonia [2, 4]. However, based on our results from the Coronavirus SARS-CoV-2 and

A complete list of the CORONADO trial investigators is provided in the Electronic supplementary material (ESM).

Bertrand Cariou, Samy Hadjadj and Matthieu Wargny contributed equally to this article.

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s00125-020-05255-9>) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

✉ Samy Hadjadj
samy.hadjadj@univ-nantes.fr

Extended author information available on the last page of the article

Diabetes Outcomes (CORONADO) study [3], other biomarkers, such as C-reactive protein, lymphocyte counts or aspartate aminotransferase, which outperformed blood glucose in multivariable analysis, could have adequate power for such a stratification and should not be forgotten.

In conclusion, whether blood glucose in COVID-19 is a causal factor requiring specific treatment or a mere marker remains to be established in future dedicated studies including randomised controlled trials.

Acknowledgements We thank sponsor (DRCI [délégation à la recherche clinique et à l'innovation]) CHU Nantes. We also thank the CORONADO Study staff at CHU Nantes, Nantes, France: Clinical Project Manager (M. Saïgues) and assistant (J. Saunier), Clinical Research Associates (S. El Andaloussi, J. Martin-Gauthier, E. Rebouilleau) and data managers (B. Guyomarch, T. Roman). We acknowledge all medical staff involved in the diagnosis and treatment of patients with COVID-19 in CORONADO participating centres. We thank the Société Francophone du Diabète (SFD) and Société Française d'Endocrinologie (SFE) for disseminating study design and organisation and the Fédération Française des Diabétiques (FFD) for participating in the study organisation.

Funding The CORONADO study received funding from: the Fondation Francophone de Recherche sur le Diabète (FFRD), supported by Novo Nordisk, MSD, Abbott, AstraZeneca, Lilly and FFD (Fédération Française des Diabétiques) – CORONADO initiative emergency grant; Société Francophone du Diabète (SFD) - CORONADO initiative emergency grant, and CHU Nantes (Fonds de Dotation-projet CORONADO). All research facilities are acknowledged for providing research associates and research technicians for clinical investigations pro bono. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The study sponsor/funder was not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.

Authors' relationships and activities BC reports grants and personal fees from Amgen, personal fees from AstraZeneca, personal fees from Akcea, personal fees from Genfit, personal fees from Gilead, personal fees from Eli Lilly, personal fees from Novo Nordisk, personal fees from MSD, grants and personal fees from Sanofi, and grants and personal fees from Regeneron. SH reports personal fees and non-financial support from AstraZeneca, grants and personal fees from Bayer, personal fees from Boehringer Ingelheim, grants from Dinno Santé, personal fees from Eli Lilly, non-financial support from Novo Nordisk, non-financial support from MSD, personal fees from Novartis, personal fees and non-financial support from Novo Nordisk, grants from Pierre Fabre Santé, personal fees and non-financial support from Sanofi, personal fees and non-financial support from Servier, and personal fees from Valbiotis. MW reports personal fees from Novo Nordisk. MP reports personal fees and non-financial support from Novo Nordisk, non-financial support from Sanofi, and non-financial support from Amgen. SB reports personal fees from Novo Nordisk, personal fees from Sanofi, personal fees from Eli Lilly, personal fees from Medtronic, and personal fees from Abbott. PD reports personal fees from Novo Nordisk, personal fees from Sanofi, personal fees from Eli Lilly, personal fees from MSD, personal fees from Novartis, personal fees from Abbott, personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, and personal fees from Mundipharma. BG reports personal fees from Eli Lilly, personal fees from Novo Nordisk, personal fees from Mellitus Care, personal fees from Isis Diabetes, and grants from Boehringer Ingelheim. MJ reports personal

fees and non-financial support from Sanofi, personal fees and non-financial support from Eli Lilly, personal fees and non-financial support from Novo Nordisk, grants and personal fees from Boehringer Ingelheim, grants, personal fees and non-financial support from Medtronic, personal fees and non-financial support from Abbott, personal fees and non-financial support from BMS, personal fees and non-financial support from MSD, and grants, personal fees and non-financial support from AstraZeneca. LP reports personal fees and non-financial support from Sanofi, personal fees and non-financial support from Eli Lilly, personal fees and non-financial support from Novo Nordisk, and personal fees and non-financial support from MSD. RR reports grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Novo Nordisk, personal fees and non-financial support from Eli Lilly, personal fees from Mundipharma, personal fees from Janssen, personal fees from Servier, grants and personal fees from AstraZeneca, personal fees from MSD, personal fees from Medtronic, personal fees from Abbott, grants from Diabnext, and personal fees from Applied Therapeutics. JFG reports personal fees and non-financial support from Eli Lilly, personal fees and non-financial support from Novo Nordisk, personal fees and non-financial support from Gilead, and personal fees and non-financial support from AstraZeneca. PG reports personal fees from Abbott, personal fees from Amgen, personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Eli Lilly, personal fees from MSD, personal fees from Mundipharma, grants and personal fees from Novo Nordisk, personal fees from Sanofi, and personal fees from Servier. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

Contribution statement BC, JFG, PG, SH, MP and MW were responsible for the concept and design. SH and BC drafted the manuscript. All authors critically revised the manuscript for important intellectual content and approved the final version of the text. Fundraising for the CORONADO study was carried out by BC, PG, SH, MP and BB.

References

1. Sardu C, D'Onofrio N, Balestrieri ML et al (2020) Hyperglycaemia on admission to hospital and COVID-19. *Diabetologia*. <https://doi.org/10.1007/s00125-020-05216-2>
2. Lepper PM, Bals R, Jüni P, von Eynatten M (2020) Blood glucose, diabetes and metabolic control in patients with community-acquired pneumonia. *Diabetologia*. <https://doi.org/10.1007/s00125-020-05225-1>
3. Cariou B, Hadjadj S, Wargny M et al (2020) Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. *Diabetologia* 63:1500–1515. <https://doi.org/10.1007/s00125-020-05180-x>
4. Lepper PM, Ott S, Nüesch E et al (2012) Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. *BMJ* 344:e3397. <https://doi.org/10.1136/bmj.e3397>
5. Van den Berghe G, Wilmer A, Hermans G et al (2006) Intensive insulin therapy in the medical ICU. *N Engl J Med* 354:449–461. <https://doi.org/10.1056/NEJMoa052521>

- ¹ Département d'Endocrinologie, Diabétologie et Nutrition, l'institut du thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093 Nantes Cedex 01, France
- ² CIC-EC 1413, Clinique des Données, CHU Nantes, Nantes, France
- ³ Département d'Endocrinologie, Diabétologie et Nutrition, CHU Amiens, PeriToxUMR_I 01, Université de Picardie, Amiens, France
- ⁴ Département d'Endocrinologie, Diabétologie, Nutrition, CHU de Angers, Angers, France
- ⁵ Département de Diabétologie, Centre Hospitalier Sud Francilien, Corbeil Essonne, France
- ⁶ Département d'Endocrinologie, Diabétologie et Maladies Métaboliques, Centre Hospitalier Bretagne Atlantique, Vannes, France
- ⁷ Clinique d'Endocrinologie Marc-Linquette, Hôpital Claude-Huriez, CHRU de Lille, Lille, France
- ⁸ Département de Diabétologie, H.I.A. Begin, Saint Mandé, France
- ⁹ Fondation Francophone pour la Recherche sur le Diabète (FFRD), Paris, France
- ¹⁰ Département d'Endocrinologie, Diabétologie et Nutrition, CHU de Besançon, Besançon, France
- ¹¹ Département d'Endocrinologie, Diabétologie et Nutrition, Assistance Publique Hôpitaux de Paris, Université Paris Saclay, Hôpital Antoine Bécère, Clamart, Hôpital Bicêtre, Le Kremlin Bicêtre, France
- ¹² Sorbonne Université, Assistance Publique Hôpitaux de Paris, Département de Diabétologie, CHU La Pitié Salpêtrière-Charles Foix, Inserm, UMR_S 1138, Centre de Recherche des Cordeliers, Paris 06, Institute of Cardiometabolism and Nutrition ICAN, Paris, France
- ¹³ Département des Maladies Infectieuses et Tropicales, CHU Nantes, Nantes, France
- ¹⁴ Département des Maladies Infectieuses et Tropicales, CHU de Poitiers, INSERM U1070, Poitiers, France
- ¹⁵ Société de Pathologie Infectieuse de langue Française (SPILF), Paris, France
- ¹⁶ Fédération Française des Diabétiques (FFD), Paris, France
- ¹⁷ Assistance Publique Hôpitaux de Paris, Hôpital Avicenne, Université Paris 13, Sorbonne Paris Cité, Département d'Endocrinologie, Diabétologie et Nutrition, CRNH-IdF, CINFO, Bobigny, France
- ¹⁸ Université Paris 13, Sorbonne Paris Cité, UMR U557 Inserm / U11125 INRAE / CNAM / Université Paris13, Unité de Recherche Epidémiologique Nutritionnelle, Bobigny, France
- ¹⁹ Département d'Endocrinologie et de Diabétologie, Hôpital de la Conception, Assistance Publique Hôpitaux de Marseille, Marseille, France
- ²⁰ Département d'Endocrinologie, Diabétologie et Nutrition, Hospices Civils de Lyon, CarMeN Laboratory, Inserm 1060, Lyon, France, Université Claude Bernard Lyon 1, Lyon, France
- ²¹ Département d'Endocrinologie et de Diabétologie, Centre Hospitalier Départemental de Vendée, La Roche sur Yon, France
- ²² Département d'Endocrinologie et de Diabétologie, Hôpital Nord, Assistance Publique Hôpitaux de Marseille, Marseille, France
- ²³ Département de Diabétologie, CHU de Caen, Caen, France
- ²⁴ Département d'Endocrinologie, CHU de Brest, EA 3878 GETBO, Brest, France
- ²⁵ CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), Université de Rennes, Rennes, France
- ²⁶ Département d'Endocrinologie et de Diabétologie, Centre Hospitalier St. Joseph - St. Luc, Lyon, France
- ²⁷ Département d'Endocrinologie, Diabétologie et Nutrition, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
- ²⁸ Département d'Endocrinologie, Diabétologie et Nutrition, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Centre de Recherche des Cordeliers, Inserm, Université de Paris, U-1138 Paris, France
- ²⁹ Département d'Endocrinologie, Diabétologie et Maladies Métaboliques, CHU de Rouen, Université de Rouen, Rouen, France
- ³⁰ Département Diabète et Endocrinologie, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France
- ³¹ Paris Diderot–Paris VII Université, Paris, France

32

Inserm UMRS 1138, Université Paris Diderot–Paris VII, Sorbonne Paris Cité, Paris, France

33

Université de Poitiers, CIC Inserm 1402, Poitiers, Médecine Intensive Réanimation, Poitiers, France

34

Centre d’Investigation Clinique CIC 1402, Université de Poitiers, Inserm, CHU de Poitiers, Poitiers, France

35

Département d’Endocrinologie, Diabète, Nutrition et CIC Inserm 1411, CHU de Montpellier, Montpellier, France

36

Centre du Diabète DIAB-eCARE, Hospices Civils de Lyon et Laboratoire CarMeN, Inserm, INRA, INSA, Université Claude Bernard Lyon 1, Lyon, France

37

Société Francophone du Diabète (SFD), Paris, France

38

Département d’Endocrinologie, Diabétologie et Nutrition, CHU Toulouse, Institut des Maladies Métaboliques et Cardiovasculaires, UMR1048 Inserm/UPS, Université de Toulouse, Toulouse, France

39

Assistance Publique Hôpitaux de Paris, Saint-Antoine Hospital, Reference Center of Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Department of Endocrinology, Paris, France

40

Inserm UMRS 938, Saint-Antoine Research Center, Sorbonne University, Paris, France